Analysis of clinical efficacy of CyberKnife® treatment for locally advanced pancreatic cancer

Abstract

Yongchun Song, Zhiyong Yuan, Fengtong Li, Yang Dong, Hongqing Zhuang, Jingsheng Wang, Huaming Chen, Ping Wang Department of Radiation Oncology and CyberKnife Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, People’s Republic of China Objective: To evaluate the efficacy and safety of CyberKnife® treatment for locally-advanced pancreatic cancer (LAPC).Methods: The efficacy of CyberKnife® treatment was analyzed in 59 LAPC patients treated between October 2006 and September 2014. The median tumor volume was 27.1 mL (13.0–125.145 mL). The median prescribed dose was 45 Gy (35–50 Gy), delivered in 5 fractions (3–8 fractions). The overall survival (OS) rates and freedom from local progression (FFLP) rates were estimated using the Kaplan–Meier survival curve.Results: The median follow-up for all patients was 10.9 months (3.2–48.7 months) and 15.6 months (3.9–37.6 months) among surviving patients. The median OS was 12.5 months, and the 1-year and 2-year survival rates were 53.9% and 35.1%, respectively. The 1-year FFLP rate was 90.8% based on the computed tomography (CT) evaluation. Grade 1–2 acute and late-stage gastrointestinal (GI) reactions were observed in 61% of the patients. One patient experienced grade 3 toxicity.Conclusion: Excellent clinical efficacy was obtained after treatment of LAPC using CyberKnife®, with minimal toxicity. Keywords: pancreatic cancer, stereotactic body radiotherapy, CyberKnife®, local control, toxicity